Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China · Delayed Price · Currency is CNY | Market Cap | 60.74B +35.3% |
| Revenue (ttm) | 5.06B +31.0% |
| Net Income | 767.58M +119.2% |
| EPS | 0.69 +123.0% |
| Shares Out | 1.11B |
| PE Ratio | 79.52 |
| Forward PE | 77.67 |
| Dividend | 0.27 (0.49%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 7,827,143 |
| Average Volume | 7,104,444 |
| Open | 57.62 |
| Previous Close | 57.66 |
| Day's Range | 54.33 - 59.00 |
| 52-Week Range | 40.70 - 62.65 |
| Beta | -0.12 |
| RSI | 46.83 |
| Earnings Date | Apr 13, 2026 |
About SHE:002653
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and... [Read more]
Financial Performance
In 2025, SHE:002653's revenue was 4.39 billion, an increase of 17.91% compared to the previous year's 3.72 billion. Earnings were 259.58 million, a decrease of -34.36%.
Financial StatementsNews
As China’s biotech firms shift gears, can AI floor the accelerator?
A quarter featuring multiple eye-popping deals is no longer unusual for China’s pharmaceutical industry – in fact, it may soon be considered a slow season. In recent months, companies including CSPC P...